T helper cell-mediated in vitro responses of recently and remotely infected subjects to a candidate recombinant vaccine for human parvovirus b19

J Infect Dis. 2001 Mar 1;183(5):805-9. doi: 10.1086/318819. Epub 2001 Jan 29.

Abstract

T cell proliferation to human parvovirus B19 antigen was measured in 6 patients with recent B19 infection (1 with pneumonia and pleuritis), 1 patient with symptoms persisting >180 days after onset, 18 nonsymptomatic subjects with remote B19 immunity, and 12 B19-seronegative control subjects. Recombinantly expressed virus-like particles (VP1/2 capsids), a candidate B19 vaccine, were used as antigen. Virus-specific T helper cell proliferation was detectable in all the recently infected patients and in most (17/18) of the remotely infected subjects but not in the seronegative control subjects. The B19-specific T cell responses, in general, were most vigorous among the recently infected patients. However, such strong B19-specific proliferation was not confined within the acute phase, as 28% (5/18) of the remotely infected healthy individuals had B19-specific reactivity persisting at acute-phase levels, apparently for years or decades. These data indicate that B cells recognizing the VP1/2 capsids receive class II-restricted help from CD4(+) T lymphocytes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute-Phase Reaction
  • Adult
  • Antigens, Viral / immunology
  • B-Lymphocytes / immunology
  • Capsid / genetics
  • Capsid / immunology
  • Cells, Cultured
  • Female
  • Humans
  • Male
  • Middle Aged
  • Parvoviridae Infections / prevention & control*
  • Parvovirus B19, Human / genetics
  • Parvovirus B19, Human / immunology*
  • T-Lymphocytes, Helper-Inducer / immunology*
  • Vaccines, Synthetic / immunology*
  • Viral Vaccines / immunology*

Substances

  • Antigens, Viral
  • Vaccines, Synthetic
  • Viral Vaccines